View clinical trials related to Pancreatic Cancer.
Filter by:An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
The drug for this submission is Hope Biosciences' allogeneic, first blood relative, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Pancreatic Cancer (PC). PC is an extremely infiltrative neoplasm that usually presents with vascular and perineural invasion in surgically resected tumors. Metastases to lymph nodes, liver and distant sites are all very common. Its incidence has markedly increased over the past several decades and ranks as the fourth leading cause of cancer death in the United States. Despite the high mortality rate associated with pancreatic cancer, its etiology is poorly understood. PC patients experience physiological symptoms such as anemia, ascites, severe fatigue, pain, cachexia, weakness, insomnia, confusion, and memory loss. The aggressive nature of PC leads to rapid deterioration of patients' quality of life and diminished ability to participate in treatment.
The purpose of this study is to evaluate the safety and efficacy of nano drug interventional therapy using digital subtraction angiography(DSA) for pancreatic cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.